Overview

For hospital pharmacies and distributors, a 73-gene lung cancer report is only as strong as the workflow around it; sourcing the service means weighing interpretation quality and reliability, not just the marker total. The panel bundles sixty-three targeted-therapy and thirty-six chemotherapy-associated markers into one next-generation sequencing result. This checklist helps B2B buyers assess providers before committing volume, so the deliverable actually supports clinical decisions. A disciplined sourcing process therefore protects both the clinical utility of the result and the buyer's standing in the market, since a weak report reflects on the distributor as much as on the original laboratory.

Confirming Scope and Report Quality

Start by mapping the sixty-three targeted markers and thirty-six chemotherapy markers to the decisions your clinicians actually make. A useful provider delivers a structured report that separates confirmed alterations from variants of unknown significance and cites the therapy or trial context. Avoid services that return a long gene list with no clear interpretation pathway, since unstructured output shifts the analysis burden back onto your own staff.

Validating the Laboratory and Turnaround

Request current accreditation and analytical validation for the reported genes, since these underpin result quality. Turnaround time matters for treatment planning, so confirm the realistic window from sample receipt to signed report rather than a best-case figure. A provider with transparent sample-handling and clear rejection criteria reduces downstream friction for your own operations team and limits disputed or repeated draws.

Logistics, Pricing and Continuity

Compare pricing per report against included markers and re-test policy, and verify shipping requirements for the sample type. Where you resell the service, confirm white-label or co-branding options and data-security terms. Finally, assess the provider's capacity to sustain volume so a single batch failure does not interrupt your customers' care pathways or erode trust in the relationship.

FAQ

Q: What should a 73-gene report include beyond the gene list? A: It should separate actionable alterations from variants of unknown significance and give therapy or trial context for the confirmed findings.

Q: How do I verify a testing provider's quality? A: Request current accreditation, analytical validation data, and clear sample-handling and turnaround commitments before signing volume.

Q: Is the chemotherapy marker set clinically settled? A: Chemotherapy-associated markers are decision-support signals, not standalone prescriptions; they should be interpreted alongside standard pathology and the treating team's judgment.